In Brief This Week: Agendia; Gen-Probe, Neogen; Synthetic Biology Industry Association; Biodesign Institute, Intel | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia this week said that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the firm's MammaPrint test. It said patients in the US can now submit claims for the MammaPrint test directly to Palmetto GBA in California where the test results are analyzed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.